A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: A Bayesian randomized serial N-of-1 trials design

Supportive Care in Cancer

Volumn 14, Issue 3, 2006, Pages 268-276

  Nathan, P C ^a   Tomlinson, G ^b,c   Dupuis, L L ^a,b   Greenberg, M L ^a   Ota, S ^a   Bartels, U ^a   Feldman, B M ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Anti emetics; Bayes Theorem; Child; Metopimazine; Ondansetron

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DIMENHYDRINATE; DOMPERIDONE; ETOPOSIDE; LOMUSTINE; LORAZEPAM; METOPIMAZINE; ONDANSETRON; PLACEBO; VINCRISTINE;

ARTICLE; BAYES THEOREM; BRAIN CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISTRESS SYNDROME; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; FEMALE; HUMAN; MALE; MEDULLOBLASTOMA; MONOTHERAPY; NEUROECTODERM TUMOR; ORTHOSTATIC HYPOTENSION; PILOT STUDY; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SEDATION; SIDE EFFECT; STATISTICAL MODEL; TASTE; TREATMENT OUTCOME;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; BAYES THEOREM; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CISPLATIN; CYCLOPHOSPHAMIDE; DOUBLE-BLIND METHOD; DRUG THERAPY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISONIPECOTIC ACIDS; MALE; NAUSEA; ONDANSETRON; ONTARIO; PILOT PROJECTS; TREATMENT OUTCOME; VOMITING;

EID: 32644479001     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-005-0875-7     Document Type: Article

References (23)

1. Dando TM, Peny CM (2004) Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 64:777-794
2. Debray H, Guihard J, Peyramond D, Tron P (1990) Treatment of vomiting in infants and children induced by acute infectious pathology. A comparative study of alizapride versus metopimazine. Ann Pediatr (Paris) 37:683-687
3. Donelli MG, Zucchetti M, D'Incalci M (1992) Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 30:251-260
4. Dupuis LL, Nathan PC (2003) Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children. Paediatr Drugs 5:597-613
5. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17:2971-2994
6. Gralla RJ, Roila F, Tonato M (2005) The 2004 Perugia Antiemetic Consensus Guideline process: methods, procedures, and participants. Support Care Cancer 13:77-79
7. Grant M (1997) Nausea and vomiting, quality of life, and the oncology nurse. Oncol Nurs Forum 24:5-7
8. Herrstedt J, Sigsgaard T, Boesgaard M, Jensen TP, Dombernowsky P (1993) Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 328:1076-1080
9. Herrstedt J, Sigsgaard T, Angelo HR, Kampmann JP, Hansen M (1997) Dose-finding study of oral metopimazine. Support Care Cancer 5:38-43
10. Herrstedt J, Sigsgaard T, Handberg J, Schousboe BM, Hansen M, Dombernowsky P (1997) Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer. J Clin Oncol 15:1690-1696
11. Herrstedt J (1998) Chemotherapy-induced nausea and vomiting with special emphasis on metopimazine. Dan Med Bull 45:412-422
12. Hesketh PJ (1999) Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 4:191-196
13. Johannessen T (1991) Controlled trials in single subjects. 1. Value in clinical medicine. BMJ 303:173-174
14. Kourtopoulos H, Holm SE, Norrby SR (1983) The influence of steroids on the penetration of antibiotics into brain tissue and brain abscesses. An experimental study in rats. J Antimicrob Chemother 11:245-249
15. Lebeau B, Depierre A, Giovannini M, Riviere A, Kaluzinski L, Votan B, Hedouin M, d'Allens H (1997) The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group. Ann Oncol 8:887-892
16. Lewis RJ, Wears RL (1993) An introduction to the Bayesian analysis of clinical trials. Ann Emerg Med 22:1328-1336
17. Osoba D, Zee B, Warr D, Kaizer L, Latreille J, Pater J (1996) Quality of life studies in chemotherapy-induced emesis. Oncology 53:92-95
18. Roila F, Aapro M, Stewart A (1998) Optimal selection of antiemetics in children receiving cancer chemotherapy. Support Care Cancer 6:215-220
19. Roila F, Donati D, Tamberi S, Margutti G (2002) Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 10:88-95
20. Schatz IJ, Bannister R, Freeman RL, Goetz CG, Jankovic J, Kaufman HC, Koller WC, Low PA, Mathias CJ, Polinsky RJ, Quinn NP, Robertson D, Streeten DHP (1996) Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. J Neurol Sci 144:218-219
21. Straathof CS, van den Bent MJ, Ma J, Schmitz PI, Kros JM, Stoter G, Vecht CJ, Schellens JH (1998) The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor. J Neuro-Oncol 37:1-8
22. Weller M, Schmidt C, Roth W, Dichgans J (1997) Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone? Neurology 48:1704-1709
23. Zucker DR, Schmid CH, McIntosh MW, D'Agostino RB, Selker HP, Lau J (1997) Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment. J Clin Epidemiol 50:401-410